871250-54-3

Upstream product

• 58620-93-2 tert-butyl 3-aminopropanoate hydrochloride 
• 99-96-7 4-hydroxy-benzoic acid 

Downstream Products

• 1195950-95-8 C₂₇H₂₉NO₆ 
• 1195950-97-0 C₃₄H₃₁Cl₂N₃O₅ 
• 1195950-99-2 C₃₀H₂₃Cl₂N₃O₅ 
• 1195950-98-1 C₃₁H₂₅Cl₂N₃O₅ 
• 1195951-16-6 C₃₄H₃₂ClN₃O₅ 
• 1195951-17-7 C₃₀H₂₄ClN₃O₅ 
• 1195950-96-9 C₃₀H₃₄N₂O₆ 
• 1195951-15-5 C₂₈H₂₉N₃O₅ 
• 1195951-32-6 C₂₇H₂₈N₂O₆ 
• 871250-53-2 3-{4-[2-cyclohexyl-1-(4'-trifluoromethyl-biphenyl-4-yl)-ethoxy]-benzoylamino}-propionic acid tert-butyl ester 
• 871252-56-1 3-{4-[2-(6-chloro-pyridin-3-yl)-octyloxy]-benzoylamino}-propionic acid tert-butyl ester 
• 871251-41-1 (R,S)-3-{4-[1-(6-chloro-pyridin-3-yl)-hexyloxy]-benzoylamino}-propionic acid tert-butyl ester 

Relevant academic research and scientific papers

GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE

The present invention relates to compounds of general formula (I), wherein ring A, ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.